259 related articles for article (PubMed ID: 8413267)
1. Dimerization mediated through a leucine zipper activates the oncogenic potential of the met receptor tyrosine kinase.
Rodrigues GA; Park M
Mol Cell Biol; 1993 Nov; 13(11):6711-22. PubMed ID: 8413267
[TBL] [Abstract][Full Text] [Related]
2. Autophosphorylation modulates the kinase activity and oncogenic potential of the Met receptor tyrosine kinase.
Rodrigues GA; Park M
Oncogene; 1994 Jul; 9(7):2019-27. PubMed ID: 8208547
[TBL] [Abstract][Full Text] [Related]
3. Efficient cell transformation by the Tpr-Met oncoprotein is dependent upon tyrosine 489 in the carboxy-terminus.
Fixman ED; Naujokas MA; Rodrigues GA; Moran MF; Park M
Oncogene; 1995 Jan; 10(2):237-49. PubMed ID: 7838524
[TBL] [Abstract][Full Text] [Related]
4. Identification of tyrosine 489 in the carboxy terminus of the Tpr-Met oncoprotein as a major site of autophosphorylation.
Kamikura DM; Naujokas MA; Park M
Biochemistry; 1996 Jan; 35(3):1010-7. PubMed ID: 8547236
[TBL] [Abstract][Full Text] [Related]
5. A multifunctional docking site mediates signaling and transformation by the hepatocyte growth factor/scatter factor receptor family.
Ponzetto C; Bardelli A; Zhen Z; Maina F; dalla Zonca P; Giordano S; Graziani A; Panayotou G; Comoglio PM
Cell; 1994 Apr; 77(2):261-71. PubMed ID: 7513258
[TBL] [Abstract][Full Text] [Related]
6. The full oncogenic activity of Ret/ptc2 depends on tyrosine 539, a docking site for phospholipase Cgamma.
Borrello MG; Alberti L; Arighi E; Bongarzone I; Battistini C; Bardelli A; Pasini B; Piutti C; Rizzetti MG; Mondellini P; Radice MT; Pierotti MA
Mol Cell Biol; 1996 May; 16(5):2151-63. PubMed ID: 8628282
[TBL] [Abstract][Full Text] [Related]
7. Identification of mutations in the coding sequence of the proto-oncogene c-kit in a human mast cell leukemia cell line causing ligand-independent activation of c-kit product.
Furitsu T; Tsujimura T; Tono T; Ikeda H; Kitayama H; Koshimizu U; Sugahara H; Butterfield JH; Ashman LK; Kanayama Y
J Clin Invest; 1993 Oct; 92(4):1736-44. PubMed ID: 7691885
[TBL] [Abstract][Full Text] [Related]
8. The DNA rearrangement that generates the TRK-T3 oncogene involves a novel gene on chromosome 3 whose product has a potential coiled-coil domain.
Greco A; Mariani C; Miranda C; Lupas A; Pagliardini S; Pomati M; Pierotti MA
Mol Cell Biol; 1995 Nov; 15(11):6118-27. PubMed ID: 7565764
[TBL] [Abstract][Full Text] [Related]
9. Structural and functional domains critical for constitutive activation of the HGF-receptor (Met).
Zhen Z; Giordano S; Longati P; Medico E; Campiglio M; Comoglio PM
Oncogene; 1994 Jun; 9(6):1691-7. PubMed ID: 8183564
[TBL] [Abstract][Full Text] [Related]
10. Activation of the JNK pathway is essential for transformation by the Met oncogene.
Rodrigues GA; Park M; Schlessinger J
EMBO J; 1997 May; 16(10):2634-45. PubMed ID: 9184210
[TBL] [Abstract][Full Text] [Related]
11. Loss of the exon encoding the juxtamembrane domain is essential for the oncogenic activation of TPR-MET.
Vigna E; Gramaglia D; Longati P; Bardelli A; Comoglio PM
Oncogene; 1999 Jul; 18(29):4275-81. PubMed ID: 10435641
[TBL] [Abstract][Full Text] [Related]
12. The multiple endocrine neoplasia type 2B point mutation alters long-term regulation and enhances the transforming capacity of the epidermal growth factor receptor.
Pandit SD; Donis-Keller H; Iwamoto T; Tomich JM; Pike LJ
J Biol Chem; 1996 Mar; 271(10):5850-8. PubMed ID: 8621456
[TBL] [Abstract][Full Text] [Related]
13. Leucine zipper-mediated dimerization is essential for the PTC1 oncogenic activity.
Tong Q; Xing S; Jhiang SM
J Biol Chem; 1997 Apr; 272(14):9043-7. PubMed ID: 9083029
[TBL] [Abstract][Full Text] [Related]
14. Pathways downstream of Shc and Grb2 are required for cell transformation by the tpr-Met oncoprotein.
Fixman ED; Fournier TM; Kamikura DM; Naujokas MA; Park M
J Biol Chem; 1996 May; 271(22):13116-22. PubMed ID: 8662733
[TBL] [Abstract][Full Text] [Related]
15. Structural Basis of TPR-Mediated Oligomerization and Activation of Oncogenic Fusion Kinases.
Pal K; Bandyopadhyay A; Zhou XE; Xu Q; Marciano DP; Brunzelle JS; Yerrum S; Griffin PR; Vande Woude G; Melcher K; Xu HE
Structure; 2017 Jun; 25(6):867-877.e3. PubMed ID: 28528776
[TBL] [Abstract][Full Text] [Related]
16. Deletion of the ectodomain unleashes the transforming, invasive, and tumorigenic potential of the MET oncogene.
Merlin S; Pietronave S; Locarno D; Valente G; Follenzi A; Prat M
Cancer Sci; 2009 Apr; 100(4):633-8. PubMed ID: 19175607
[TBL] [Abstract][Full Text] [Related]
17. Tumorigenicity of the met proto-oncogene and the gene for hepatocyte growth factor.
Rong S; Bodescot M; Blair D; Dunn J; Nakamura T; Mizuno K; Park M; Chan A; Aaronson S; Vande Woude GF
Mol Cell Biol; 1992 Nov; 12(11):5152-8. PubMed ID: 1406687
[TBL] [Abstract][Full Text] [Related]
18. Enhanced transformation by a plasma membrane-associated met oncoprotein: activation of a phosphoinositide 3'-kinase-dependent autocrine loop involving hyaluronic acid and CD44.
Kamikura DM; Khoury H; Maroun C; Naujokas MA; Park M
Mol Cell Biol; 2000 May; 20(10):3482-96. PubMed ID: 10779338
[TBL] [Abstract][Full Text] [Related]
19. The Glu632-Leu633 deletion in cysteine rich domain of Ret induces constitutive dimerization and alters the processing of the receptor protein.
Bongarzone I; Vigano E; Alberti L; Mondellini P; Uggeri M; Pasini B; Borrello MG; Pierotti MA
Oncogene; 1999 Aug; 18(34):4833-8. PubMed ID: 10490816
[TBL] [Abstract][Full Text] [Related]
20. Constitutive activation of the RON gene promotes invasive growth but not transformation.
Santoro MM; Collesi C; Grisendi S; Gaudino G; Comoglio PM
Mol Cell Biol; 1996 Dec; 16(12):7072-83. PubMed ID: 8943362
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
